StockData
Janux Therapeutics, Inc. logo

Janux Therapeutics, Inc. (JANX) stock

JANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3040% below fair value
$10.08−0.21 (-2.04%)

Close on Nov 20, 2026Market cap $616.26MP/E –Yield –

Janux Therapeutics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

No gross profit figures for Janux Therapeutics

Janux Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Janux Therapeutics figures

See a number that looks wrong?